• Je něco špatně v tomto záznamu ?

In vitro evaluation of concentration, labeling effectiveness and stability for 131 I-labeled radioimmunoassay ligand using real-time detection technology

P. Barta, J. Janousek, K. Zilkova, F. Trejtnar,

. 2017 ; 60 (1) : 80-86. [pub] 20161213

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016866

Radioimmunoassay belongs to the analytical method enabling highly specific and sensitive quantification of molecules. The verification of the real-time radioimmunoassay technology usefulness for ligand-quality characteristics evaluation such as concentration, influence of radiolabeling on binding affinity and stability was estimated. The anti-epidermal growth factor receptor antibody 131 I-cetuximab was employed as the ligand antibody. The concentration of 131 I-cetuximab was derived from the shape of binding curves coming from the ligand-receptor interaction. The binding curves also allowed the estimation of 131 I-cetuximab binding affinity for different radiolabeling procedures (incubation times 1, 5, and 10 minutes) in stability testing up to 96 hours at 4°C. The stability testing also included comparative analysis by size exclusion high-performance liquid chromatography. The assessment of cetuximab concentrations using real-time method showed acceptable accordance between real and calculated values. The real-time method revealed that 1-minute radiolabeling proved to be the optimal incubation time for direct radioiodination of cetuximab. Stability testing showed the significant change in radioligand affinity by one order at the longest incubation times (72 and 96 hours). Characterization of stability and binding behavior of radiolabeled monoclonal antibodies by the verified real-time method before use in other assays may be employed to eliminate variability and suboptimal antibody performance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016866
003      
CZ-PrNML
005      
20180516135625.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jlcr.3478 $2 doi
035    __
$a (PubMed)27966236
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Barta, Pavel $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
245    10
$a In vitro evaluation of concentration, labeling effectiveness and stability for 131 I-labeled radioimmunoassay ligand using real-time detection technology / $c P. Barta, J. Janousek, K. Zilkova, F. Trejtnar,
520    9_
$a Radioimmunoassay belongs to the analytical method enabling highly specific and sensitive quantification of molecules. The verification of the real-time radioimmunoassay technology usefulness for ligand-quality characteristics evaluation such as concentration, influence of radiolabeling on binding affinity and stability was estimated. The anti-epidermal growth factor receptor antibody 131 I-cetuximab was employed as the ligand antibody. The concentration of 131 I-cetuximab was derived from the shape of binding curves coming from the ligand-receptor interaction. The binding curves also allowed the estimation of 131 I-cetuximab binding affinity for different radiolabeling procedures (incubation times 1, 5, and 10 minutes) in stability testing up to 96 hours at 4°C. The stability testing also included comparative analysis by size exclusion high-performance liquid chromatography. The assessment of cetuximab concentrations using real-time method showed acceptable accordance between real and calculated values. The real-time method revealed that 1-minute radiolabeling proved to be the optimal incubation time for direct radioiodination of cetuximab. Stability testing showed the significant change in radioligand affinity by one order at the longest incubation times (72 and 96 hours). Characterization of stability and binding behavior of radiolabeled monoclonal antibodies by the verified real-time method before use in other assays may be employed to eliminate variability and suboptimal antibody performance.
650    _2
$a protinádorové látky imunologicky aktivní $x chemie $x farmakologie $7 D000074322
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cetuximab $x chemie $x farmakologie $7 D000068818
650    _2
$a lidé $7 D006801
650    _2
$a radioizotopy jodu $x chemie $x farmakologie $7 D007457
650    _2
$a ligandy $7 D008024
650    _2
$a radioimunoanalýza $x metody $x normy $7 D011863
650    _2
$a radioligandová zkouška $x metody $x normy $7 D011869
650    _2
$a radiofarmaka $x chemie $x farmakologie $7 D019275
655    _2
$a časopisecké články $7 D016428
700    1_
$a Janousek, Jiri $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Zilkova, Katerina $u Department of Nuclear Medicine, Faculty Hospital Hradec Kralove, Czech Republic.
700    1_
$a Trejtnar, Frantisek $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
773    0_
$w MED00002760 $t Journal of labelled compounds & radiopharmaceuticals $x 1099-1344 $g Roč. 60, č. 1 (2017), s. 80-86
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27966236 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180516135800 $b ABA008
999    __
$a ok $b bmc $g 1300490 $s 1013706
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 60 $c 1 $d 80-86 $e 20161213 $i 1099-1344 $m Journal of labelled compounds & radiopharmaceuticals $n J Labelled Comp Radiopharm $x MED00002760
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace